Records containing: PSA Progression

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

All FDA submission records EMA medicine records ClinicalTrials.gov record updates ClinicalTrials.gov records with results posted

CLINICAL_TRIALS study record update · 2026-04-07
MRI-Assisted Guidance for Non-Essential Tissue Sampling (MAGNET): an Investigator-initiated, International, Multicentre, Prospective, Pairedcohort, Diagnostic Utility Study
CLINICAL_TRIALS study record update · 2026-03-06
A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer
CLINICAL_TRIALS study record update · 2026-01-21
A Randomized, Phase II Study of Apalutamide +/- Stereotactic Body Radiotherapy (SBRT) in Castration-Resistant Prostate Cancer Patients With Oligometastatic Disease on PSMA-PET Imaging
CLINICAL_TRIALS study record update · 2025-11-06
Prospective Study of Stereotactic Body Radiotherapy (SBRT) Following Radical Prostatectomy
CLINICAL_TRIALS study record update · 2025-10-29
A Randomized Phase 2 Trial of White Button Mushroom Supplement in Patients With Biochemically Recurrent Prostate Cancer Following Local Therapy and in Therapy Na?ve Patients With Favorable Risk Prostate Cancer Undergoing Active Surveillance
Organize your saved records without ads with Plus.
CLINICAL_TRIALS study record update · 2025-06-12
PLATI-PARP: A Phase 2 Study of Induction Docetaxel and Carboplatin Followed by Maintenance Rucaparib in Treatment of Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency
CLINICAL_TRIALS study record update · 2025-01-20
Addition of Pembrolizumab Upon Progression on Enzalutamide in Men With mCRPC
CLINICAL_TRIALS study record update · 2024-01-30
68Ga-NeoBOMB1 and 68Ga-PSMA R2 PET/MRI in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer
CLINICAL_TRIALS study record update · 2023-10-16
Phase Ib/II Study of Enzalutamide With Venetoclax (ABT-199) in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
CLINICAL_TRIALS study record update · 2023-07-14
An Open-Label, Parallel, Phase II Study of Single-Agent Oral ESK981 in Men With Castrate-Resistant Prostate Cancer (CRPC)
CLINICAL_TRIALS study record update · 2022-11-17
Docetaxel and Carboplatin for Patients With Metastatic, Castration Resistant Prostate Cancer and Inactivated Genes in BRCA 1/2 Pathway
CLINICAL_TRIALS study record update · 2022-11-15
Phase II Trial of Immune Checkpoint Inhibitor With Anti-CD3 x Anti-HER2 Bispecific Antibody Armed Activated T Cells in Metastatic Castrate Resistant Prostate Cancer
CLINICAL_TRIALS study record update · 2022-10-05
Phase Ib/II Study of Enzalutamide With Decitabine, a DNA Hypomethylating Agent, in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
CLINICAL_TRIALS study record update · 2022-04-27
A Phase II Study of sEphB4-HSA in Metastatic Castration-Resistant Prostate Cancer
CLINICAL_TRIALS study record update · 2022-01-21
18F-DCFPyL PET/CT in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer and Non-Contributory CT Scans
CLINICAL_TRIALS study record update · 2021-09-30
Impact of 68GA-PSMA-11 PET/CT on Initial and Subsequent Treatment Strategies of Patients With Prostate Cancer
CLINICAL_TRIALS study record update · 2020-09-28
Identifying Mechanisms of Resistance to Enzalutamide (MDV3100) Treatment in Men With Castration-Resistant Prostate Cancer
CLINICAL_TRIALS study record update · 2018-06-26
Phase II Single Agent Study of Selinexor (KPT-330) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Prior Therapy With Abiraterone and/or Enzalutamide